ADVM_OUT_1 [2025-04-02 14:13:29 -0400] 3223 Bytes | 834 tokens | Cum: 834 tkns (10.42% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and Adverum Biotechnologies (ADVM) hit my radar screen, up to 4.4 from a prev close of 3.83 Do you think its got more juice or is it lacking potential? It's 2:13:28 PM on Wed Apr 02, 2025 -0400 and I have to decide: buy or sell!

--- COMPANY PROFILE ---
Company: Adverum Biotechnologies (ADVM)
IPO: 2014-07-31 (10 Years Ago)
Market Cap: $82,897,815
Shares Outstanding: 20,800,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS
Description: Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

Here's the first list of news for Adverum Biotechnologies:

C1 - Mar-31-25 04:01PM - Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference
C2 - Mar-03-25 04:01PM - Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD
C3 - Feb-28-25 04:00PM - Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
C4 - Feb-25-25 07:00AM - Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference
C5 - Feb-05-25 04:05PM - Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
C6 - Dec-06-24 04:05PM - Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
C7 - Nov-20-24 04:05PM - Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
C8 - Nov-18-24 07:00AM - Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Adverum Biotechnologies (ADVM)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

ADVM_OUT_3 [2025-04-02 14:13:32 -0400] 1099 Bytes | 346 tokens | Cum: 1182 tkns (14.77% of 8k)
==========================================================================

Showing C2 (chunk 1 of 14): C2:
**Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD**
Date: Mar-03-25 04:01PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/03/3036018/32452/en/Adverum-Biotechnologies-Initiates-ARTEMIS-Phase-3-Study-Evaluating-Ixo-vec-for-Wet-AMD.html

March 03, 2025 16:01 ET| Source:Adverum Biotechnologies, Inc.Adverum Biotechnologies, Inc.

REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, today announced the initiation of the ARTEMIS Phase 3 study. This pivotal trial is designed to evaluate the efficacy and safety of Ixo-vec (ixoberogene soroparvovec) as a one-time intravitreal (IVT) injection for patients with neovascular (wet) age-related macular de

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ADVM_OUT_5 [2025-04-02 14:13:33 -0400] 924 Bytes | 261 tokens | Cum: 1511 tkns (18.89% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-01T17:11:00Z - Stocks See Support from Magnificent Seven Stocks...
A2 - 2025-04-01T16:22:00Z - Stocks Under Pressure Ahead of Wednesday's Tariff Announcement...
A3 - 2025-03-31T22:43:00Z - Equity Markets Recover on Strength in Defensive Stocks and Energy Producers...
A4 - 2025-03-31T21:05:46Z - 12 Health Care Stocks Moving In Monday's After-Market Session - AquaBounty Techs (NASDAQ:AQB), Adver...
A5 - 2025-03-31T20:15:00Z - Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Confere...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ADVM_OUT_7 [2025-04-02 14:13:37 -0400] 1098 Bytes | 266 tokens | Cum: 1779 tkns (22.24% of 8k)
==========================================================================

Showing A1 (chunk 1 of 8): A1:
**Stocks See Support from Magnificent Seven Stocks**Date: 2025-04-01Source: {'uri': 'nasdaq.com', 'dataType': 'news', 'title': 'NASDAQ Stock Market'}URL: https://www.nasdaq.com/articles/stocks-see-support-magnificent-seven-stocksStock indexes today recovered from early losses and are trading mixed due to the strength in the Magnificent Seven stocks. Stocks today initially opened lower ahead of Wednesday's announcement of new US tariffs. President Trump will announce the details of the reciprocal tariffs on Wednesday at 3 pm EST. Stock index futures extended their losses today on a report from the Washington Post that said President Trump is considering tariffs of around 20% on most imports to the US. The tariff worries have fueled risk-off sentiment in asset markets and sparked safe-haven buying of government debt and gold, with the 10-year T-note yield falling to a 4-week low today

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ADVM_OUT_9 [2025-04-02 14:13:38 -0400] 1082 Bytes | 334 tokens | Cum: 2201 tkns (27.51% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-04T15:55:00Z - 2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies
B2 - 2025-03-03T21:01:00Z - Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD
B3 - 2025-02-25T12:00:00Z - Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference
B4 - 2024-10-22T17:00:00Z - Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
B5 - 2024-07-22T14:01:42Z - What's in Store for ADMA Biologics (ADMA) in Q2 Earnings? - Zacks Investment Research
B6 - 2024-07-19T02:01:07Z - Adverum biotechnologies executive buys shares worth over $1.7 million By Investing.com - Investing.com Australia

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ADVM_OUT_11 [2025-04-02 14:13:42 -0400] 996 Bytes | 257 tokens | Cum: 2460 tkns (30.75% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/04/3036739/28124/en/2025-Market-Prospects-of-Adeno-Associated-Virus-Vectors-in-Gene-Therapy-Pipeline-200-Pipeline-Drugs-and-the-Strategic-Workings-of-180-Companies.htmlThe report provides a comprehensive analysis of the Adeno-Associated Virus (AAV) Vectors in Gene Therapy pipeline, highlighting the potential of this technology to revolutionize the treatment of genetic disorders. It examines the challenges in scalable production and safety, as well as the industry's focus on optimizing vectors for improved safety, specificity, and efficiency.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ADVM_OUT_13 [2025-04-02 14:13:43 -0400] 806 Bytes | 235 tokens | Cum: 2787 tkns (34.84% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S9 - 2024-11-18 8-K Item7.01 Regulation FD Disclosure.

On November 18, 2024, Adverum Biotechnologies, Inc. (the Company) announced positive 52-week topline data from the Companys LUNA Phase 2 clinical trial and new four-year long-term follow-up data from the Companys OPTIC extension trial of Ixobe...

S10 - 2024-11-04 10-Q PART IFIN INFO

Item 1. Fin Stmnts

Adverum Biotechnologies, Inc.

Condensed Cons Balance Sheets

(In thousands)

(Unaudited) September 30, 2024 December 31, 2023 Assets

Curr assets:

Cash and cash equiv $ 92,851 $ 75,000 Short-te...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ADVM_OUT_15 [2025-04-02 14:13:48 -0400] 1098 Bytes | 288 tokens | Cum: 3077 tkns (38.46% of 8k)
==========================================================================

Showing S9 (chunk 1 of 2): S9:
Item7.01 Regulation FD Disclosure.

On November 18, 2024, Adverum Biotechnologies, Inc. (the Company) announced positive 52-week topline data from the Companys LUNA Phase 2 clinical trial and new four-year long-term follow-up data from the Companys OPTIC extension trial of Ixoberogene soroparvovec (Ixo-vec) in patients with wet age-related macular degeneration (AMD). In connection with the data release, the Company compiled a presentation (the Presentation) that includes the data referenced above. A copy of the Presentation is furnished as Exhibit 99.1. For important information about forward-looking statements, see the slide titled Forward-Looking Statements in Exhibit 99.1 attached hereto.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as am

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ADVM_OUT_17 [2025-04-02 14:13:57 -0400] 5980 Bytes | 1812 tokens | Cum: 4983 tkns (62.29% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+----------------------+-------------------------+------------------------+
| Volume: 99,504 | Perf Month: 2.00% | Option/Short: Yes / Yes | Sales Y/Y TTM: -72.22% |
+---------------------+----------------------+-------------------------+------------------------+
| Avg Volume: 174.59K | Perf Quarter: -7.57% | Short Float: 11.57% | ROE: -76.26% |
+---------------------+----------------------+-------------------------+------------------------+
| Rel Volume: 0.81 | Index: RUT | Short Ratio: 8.49 | ROI: -45.53% |
+---------------------+----------------------+-------------------------+------------------------+
| RSI (14): 45.75 | Market Cap: 90.17M | Short Interest: 1.48M | Sales Surprise: - |
+---------------------+----------------------+-------------------------+------------------------+
| ATR (14): 0.49 | Shs Outstand: 20.80M | Beta: 1.00 | EPS Surprise: -1.40% |
+---------------------+----------------------+-------------------------+------------------------+
| SMA20: -8.96% | Shs Float: 12.81M | Sales Q/Q: - | P/E: - |
+---------------------+----------------------+-------------------------+------------------------+
| SMA50: -3.35% | Inst Own: 51.11% | Sales past 5Y: - | Earnings: Mar 26 |
+---------------------+----------------------+-------------------------+------------------------+
| SMA200: -30.28% | Insider Own: 38.42% | Employees: - | |
+---------------------+----------------------+-------------------------+------------------------+
| Perf Week: -13.99% | Insider Trans: 6.32% | Debt/Eq: 0.51 | |
+---------------------+----------------------+-------------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Adverum Biotechnologies, Inc. (ADVM) by Leonard Braden Michael (Unknown Title) on 2025-03-26
- Common Stock: 20407 shares at $5.0395 (D)
- Common Stock: 16593 shares at $5.1883 (D)

Inside Trans: Adverum Biotechnologies, Inc. (ADVM) by Leonard Braden Michael (Unknown Title) on 2025-03-18
- Common Stock: 18000 shares at $4.6 (I)
- Common Stock: 44341 shares at $4.7274 (I)
- Common Stock: 25000 shares at $4.9356 (I)
- Common Stovk: 30600 shares at $5.6133 (I)

Inside Trans: Adverum Biotechnologies, Inc. (ADVM) by Leonard Braden Michael (Unknown Title) on 2025-02-26
- Common Stock: 164886 shares at $4.0087 (I)
- Common Stock: 86802 shares at $4.4595 (I)
- Common Stock: 85068 shares at $4.5965 (I)

Inside Trans: Adverum Biotechnologies, Inc. (ADVM) by Fischer Laurent (CEO, PRESIDENT AND DIRECTOR) on 2025-02-25
- Common Stock: 25000 shares at $0 (D)
- Stock Option (Right to Buy): 150000 shares at $0 (D)

Inside Trans: Adverum Biotechnologies, Inc. (ADVM) by Ozden Rabia Gurses (Chief Medical Officer) on 2025-02-25
- Common Stock: 8125 shares at $0 (D)
- Stock Option (Right to Buy): 48750 shares at $0 (D)

Inside Trans: Adverum Biotechnologies, Inc. (ADVM) by Rubinstein Linda M (CHIEF FINANCIAL OFFICER) on 2025-02-25
- Common Stock: 8125 shares at $0 (D)
- Stock Option (Right to Buy): 48750 shares at $0 (D)

Inside Trans: Adverum Biotechnologies, Inc. (ADVM) by Seyedkazemi Setareh (CHIEF DEVELOPMENT OFFICER) on 2025-02-25
- Common Stock: 8125 shares at $0 (D)
- Stock Option (Right to Buy): 48750 shares at $0 (D)

Inside Trans: Adverum Biotechnologies, Inc. (ADVM) by Soparkar Peter (CHIEF OPERATING OFFICER) on 2025-02-25
- Common Stock: 13125 shares at $0 (D)
- Stock Option (Right to Buy): 78750 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 1000000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -94111000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 4.35
Average Volume: 149925.96
30-Day High: 5.6
30-Day Low: 3.83

[Detailed Financials: Q3 2024]
- Total Assets: $234,375,000.0
- Total Liabilities: $90,259,000.0
- Total Equity: $144,116,000.0
- Current Assets: $161,080,000.0
- Current Liabilities: $27,657,000.0

[Income Statement: Q3 2024]
- Revenue: $1,000,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -1.3

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-34,470,000.0

[Detailed Financials: Q2 2024]
- Total Assets: $253,803,000.0
- Total Liabilities: $85,774,000.0
- Total Equity: $168,029,000.0
- Current Assets: $179,418,000.0
- Current Liabilities: $22,461,000.0

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.89

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-22,287,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

ADVM_OUT_19 [2025-04-02 14:13:58 -0400] 676 Bytes | 167 tokens | Cum: 5341 tkns (66.76% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

ADVM_IN_21 [2025-04-02 14:13:59 -0400] 126 Bytes | 29 tokens | Cum: 5398 tkns (67.47% of 8k)
==========================================================================

====================================
[2025-04-02 14:13:59] # Analysis Completed
Elapsed Time: 30.67 seconds